Adagene Inc
ADAG2.630USD
+0.090+3.54%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
154.94MCap. mercado
PérdidaP/E TTM
Más Datos de Adagene Inc Compañía
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
Información de Adagene Inc
Símbolo de cotizaciónADAG
Nombre de la empresaAdagene Inc
Fecha de salida a bolsaFeb 09, 2021
Director ejecutivoLuo (Peter)
Número de empleados138
Tipo de seguridadDepository Receipt
Fin del año fiscalFeb 09
Dirección4F, Building C14, No. 218, Xinghu Street
CiudadSUZHOU
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísChina
Código postal- -
Teléfono8651287773632
Sitio Webhttps://www.adagene.com/
Símbolo de cotizaciónADAG
Fecha de salida a bolsaFeb 09, 2021
Director ejecutivoLuo (Peter)
Ejecutivos de Adagene Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Peter (Peizhi) Luo, Ph.D.
Dr. Peter (Peizhi) Luo, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
1.31M
-46664.00%
Dr. Fangyong (Felix) Du, Ph.D.
Dr. Fangyong (Felix) Du, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Dr. Xu Jc, M.D., Ph.D.
Dr. Xu Jc, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Zhao Qinghai, Ph.D.
Mr. Zhao Qinghai, Ph.D.
Chief Manufacturing Officer
Chief Manufacturing Officer
--
--
Mr. Tam (Raymond) Man Kin
Mr. Tam (Raymond) Man Kin
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Ms. Gu (Vicky) Chunfang
Ms. Gu (Vicky) Chunfang
Senior Director of Finance
Senior Director of Finance
--
--
Ms. Zhou Ling
Ms. Zhou Ling
Senior Director of Human Resources
Senior Director of Human Resources
--
--
Ms. Li Yan
Ms. Li Yan
Senior Vice President of Bioinformatics and Information Technology
Senior Vice President of Bioinformatics and Information Technology
--
--
Ms. She (Kristine) Xiaohong
Ms. She (Kristine) Xiaohong
Senior Vice President, Head of Clinical Operations
Senior Vice President, Head of Clinical Operations
--
--
Dr. Liu Guizhong, Ph.D.
Dr. Liu Guizhong, Ph.D.
Head of Biology and Pharmacology
Head of Biology and Pharmacology
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Peter (Peizhi) Luo, Ph.D.
Dr. Peter (Peizhi) Luo, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
1.31M
-46664.00%
Dr. Fangyong (Felix) Du, Ph.D.
Dr. Fangyong (Felix) Du, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Dr. Xu Jc, M.D., Ph.D.
Dr. Xu Jc, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Zhao Qinghai, Ph.D.
Mr. Zhao Qinghai, Ph.D.
Chief Manufacturing Officer
Chief Manufacturing Officer
--
--
Mr. Tam (Raymond) Man Kin
Mr. Tam (Raymond) Man Kin
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Ms. Gu (Vicky) Chunfang
Ms. Gu (Vicky) Chunfang
Senior Director of Finance
Senior Director of Finance
--
--
Desglose de ingresos
FY2024
FY2023
FY2022
FY2021
FY2020
La empresa aún no ha revelado los datos relevantes.
Por regiónUSD
Nombre
Ganancia
Proporción
China (Mainland)
103.20K
0.00%
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: sáb., 7 de feb
Actualizado: sáb., 7 de feb
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Smith (Vincent C)
10.81%
General Atlantic LLC
8.03%
Olive Tree Capital
7.57%
WuXi AppTec Co, Ltd.
7.00%
Panacea Venture
4.77%
Otro
61.82%
Accionistas
Accionistas
Proporción
Smith (Vincent C)
10.81%
General Atlantic LLC
8.03%
Olive Tree Capital
7.57%
WuXi AppTec Co, Ltd.
7.00%
Panacea Venture
4.77%
Otro
61.82%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
13.58%
Investment Advisor
13.28%
Venture Capital
12.37%
Private Equity
8.03%
Corporation
1.93%
Hedge Fund
0.35%
Research Firm
0.16%
Investment Advisor/Hedge Fund
0.02%
Otro
50.28%
Participación institucional
Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
34
16.13M
33.64%
--
2025Q3
35
16.13M
34.15%
+1.22M
2025Q2
33
14.91M
35.61%
-1.53M
2025Q1
31
16.44M
41.65%
-3.18M
2024Q4
29
17.99M
26.58%
+3.27M
2024Q3
27
14.73M
28.57%
+3.50M
2024Q2
28
11.22M
29.45%
-1.07M
2024Q1
30
12.30M
23.60%
+1.88M
2023Q4
27
7.12M
26.44%
-1.20M
2023Q3
33
8.32M
27.49%
-14.57K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
General Atlantic LLC
3.78M
8.03%
-43.61K
-1.14%
Sep 30, 2025
Olive Tree Capital
3.57M
7.57%
--
--
Feb 28, 2025
WuXi AppTec Co, Ltd.
3.30M
7%
-685.45K
-17.21%
Sep 30, 2025
Panacea Venture
2.25M
4.77%
+2.25M
--
Sep 30, 2025
HSG Holding Ltd.
1.34M
2.85%
--
--
Sep 30, 2025
Luo (Peter)
1.31M
2.77%
-46.66K
-3.45%
Feb 28, 2025
Impresa Management LLC
1.29M
2.74%
+1.29M
--
Feb 28, 2025
GP Healthcare Capital Co., Ltd.
910.00K
1.93%
+910.00K
--
Feb 28, 2025
Mill Creek Capital Advisors, LLC
199.61K
0.42%
--
--
Sep 30, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
